NF-κB Signaling Pathway and Its Therapeutic Implications in Human Diseases

REFERENCES

• Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705–716
   PubMed Web of Science ®Google Scholar
• Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921–928
   PubMed Web of Science ®Google Scholar
• Karin M., Greten F. R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749–759
   PubMed Web of Science ®Google Scholar
• Barnes P. J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1071
   PubMed Web of Science ®Google Scholar
• Anest V., Hanson J. L., Cogswell P. C., Steinbrecher K. A., Strahl B. D., Baldwin A. S. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003; 423: 659–663
   PubMed Web of Science ®Google Scholar
• Granet C., Maslinski W., Miossec P. Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther 2004; 6: R190–R198
   PubMedGoogle Scholar
• Zhu Y. M., Bradbury D. A., Pang L., Knox A. J. Transcriptional regulation of interleukin (IL)-8 by bradykinin in human airway smooth muscle cells involves prostanoid-dependent activation of AP-1 and nuclear factor (NF)-IL-6 and prostanoid-independent activation of NF-kappaB. J Biol Chem 2003; 278: 29366–29375
   Google Scholar
• Hseu Y. C., Wu F. Y., Wu J. J., Chen J. Y., Chang W. H., Lu F. J., Lai Y. C., Yang H. L. Anti-inflammatory potential of Antrodia camphorata through inhibition of iNOS, COX-2 and cytokines via the NF-kappaB pathway. Int Immunopharmacol 2005; 5: 1914–1925
   PubMed Web of Science ®Google Scholar
• Kiemer A. K., Hartung T., Huber C., Vollmar A. M. Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-kappaB pathway. J Hepatol 2003; 38: 289–297
   PubMed Web of Science ®Google Scholar
• Jobin C., Morteau O., Han D. S., Balfour S. R. Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998; 95: 537–543
   PubMed Web of Science ®Google Scholar
• Van Antwerp D. J., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787–789
   PubMed Web of Science ®Google Scholar
• Wu M., Lee H., Bellas R. E., Schauer S. L., Arsura M., Katz D., FitzGerald M. J., Rothstein T. L., Sherr D. H., Sonenshein G. E. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J 1996; 15: 4682–4690
   PubMed Web of Science ®Google Scholar
• Helbig G., Christopherson K. W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K. D., Broxmeyer H. E., Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003; 278: 21631–21638
   PubMed Web of Science ®Google Scholar
• Huang S., Pettaway C. A., Uehara H., Bucana C. D., Fidler I. J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188–4197
   PubMed Web of Science ®Google Scholar
• Samant R. S., Clark D. W., Fillmore R. A., Cicek M., Metge B. J., Chandramouli K. H., Chambers A. F., Casey G., Welch D. R., Shevde L. A. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007; 6: 6
   Google Scholar
• van den B. R., Haenen G. R., van den B. H., Bast A. Transcription factor NF-kappaB as a potential biomarker for oxidative stress. Br J Nutr 2001; 86(Suppl 1)S121–S127
   Google Scholar
• Davis J. N., Kucuk O., Djuric Z., Sarkar F. H. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 2001; 30: 1293–1302
   PubMed Web of Science ®Google Scholar
• Deng L., Lin-Lee Y. C., Claret F. X., Kuo M. T. 2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem 2001; 276: 413–420
   PubMed Web of Science ®Google Scholar
• Galaris D., Evangelou A. The role of oxidative stress in mechanisms of metal-induced carcinogenesis. Crit Rev Oncol Hematol 2002; 42: 93–103
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431–436
   PubMed Web of Science ®Google Scholar
• Finkel T., Holbrook N. J. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239–247
   PubMed Web of Science ®Google Scholar
• Ho E., Bray T. M. Antioxidants, NFkappaB activation, and diabetogenesis. Proc Soc Exp Biol Med 1999; 222: 205–213
   PubMed Web of Science ®Google Scholar
• Lamhamedi-Cherradi S. E., Zheng S., Hilliard B. A., Xu L., Sun J., Alsheadat S., Liou H. C., Chen Y. H. Transcriptional regulation of type I diabetes by NF-kappa B. J. Immunol 2003; 171: 4886–4892
   PubMedGoogle Scholar
• Mollah Z. U., Pai S., Moore C., O'Sullivan B. J., Harrison M. J., Peng J., Phillips K., Prins J. B., Cardinal J., Thomas R. Abnormal NF-kappa B function characterizes human type 1 diabetes dendritic cells and monocytes. J Immunol 2008; 180: 3166–3175
   PubMedGoogle Scholar
• Beal M. F. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002; 32: 797–803
   PubMed Web of Science ®Google Scholar
• Kaltschmidt B., Uherek M., Volk B., Baeuerle P. A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U. S. A 1997; 94: 2642–2647
   PubMed Web of Science ®Google Scholar
• Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., Faucheux B. A., Agid Y., Hirsch E. C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U. S. A 1997; 94: 7531–7536
   PubMed Web of Science ®Google Scholar
• Simmonds R. E., Foxwell B. M. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008; 47: 584–590
   PubMed Web of Science ®Google Scholar
• Hajra L., Evans A. I., Chen M., Hyduk S. J., Collins T., Cybulsky M. I. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci U. S. A 2000; 97: 9052–9057
   PubMed Web of Science ®Google Scholar
• Isomoto H., Mizuta Y., Miyazaki M., Takeshima F., Omagari K., Murase K., Nishiyama T., Inoue K., Murata I., Kohno S. Implication of NF-kappaB in Helicobacter pylori-associated gastritis. Am. J. Gastroenterol 2000; 95: 2768–2776
   PubMed Web of Science ®Google Scholar
• Schreiber S., Nikolaus S., Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42: 477–484
   PubMed Web of Science ®Google Scholar
• Brown M. A., Jones W. K. NF-kappaB action in sepsis: the innate immune system and the heart. Front. Biosci 2004; 9: 1201–1217
   Google Scholar
• Burgos P., Metz C., Bull P., Pincheira R., Massardo L., Errazuriz C., Bono M. R., Jacobelli S., Gonzalez A. Increased expression of c-rel, from the NF-kappaB/Rel family, in T cells from patients with systemic lupus erythematosus. J Rheumatol 2000; 27: 116–127
   PubMedGoogle Scholar
• Bauerova K., Bezek A. Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen Physiol Biophys 1999; 18: 15–20, (Spec No)
   PubMed Web of Science ®Google Scholar
• Yoshizumi M., Tsuchiya K., Tamaki T. Signal transduction of reactive oxygen species and mitogen-activated protein kinases in cardiovascular disease. J Med Invest 2001; 48: 11–24
   PubMedGoogle Scholar
• Yamamoto Y., Gaynor R. B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135–142
   PubMed Web of Science ®Google Scholar
• Bharti A. C., Aggarwal B. B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883–888
   PubMed Web of Science ®Google Scholar
• Algul H., Treiber M., Lesina M., Schmid R. M. Mechanisms of disease: chronic inflammation and cancer in the pancreas—a potential role for pancreatic stellate cells?. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 454–462
   PubMedGoogle Scholar
• Perwez H. S., Harris C. C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373–2380
   Google Scholar
• Bargou R. C., Emmerich F., Krappmann D., Bommert K., Mapara M. Y., Arnold W., Royer H. D., Grinstein E., Greiner A., Scheidereit C., Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961–2969
   PubMed Web of Science ®Google Scholar
• Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., Munshi N., Dang L., Castro A., Palombella V., Adams J., Anderson K. C. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–16647
   PubMed Web of Science ®Google Scholar
• Nakshatri H., Bhat-Nakshatri P., Martin D. A., Goulet R. J., Jr., Sledge G. W., Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629–3639
   PubMed Web of Science ®Google Scholar
• Shukla S., MacLennan G. T., Fu P., Patel J., Marengo S. R., Resnick M. I., Gupta S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004; 6: 390–400
   PubMed Web of Science ®Google Scholar
• Li L., Aggarwal B. B., Shishodia S., Abbruzzese J., Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101: 2351–2362
   PubMed Web of Science ®Google Scholar
• Holcomb B., Yip-Schneider M., Schmidt C. M. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008; 36: 225–235
   Google Scholar
• Levidou G., Korkolopoulou P., Nikiteas N., Tzanakis N., Thymara I., Saetta A. A., Tsigris C., Rallis G., Vlasis K., Patsouris E. Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance. Virchows Arch 2007; 450: 519–527
   Google Scholar
• Allen C. T., Ricker J. L., Chen Z., Van W. C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 959–971
   PubMed Web of Science ®Google Scholar
• Liptay S., Weber C. K., Ludwig L., Wagner M., Adler G., Schmid R. M. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003; 105: 735–746
   PubMed Web of Science ®Google Scholar
• Fujioka S., Sclabas G. M., Schmidt C., Frederick W. A., Dong Q. G., Abbruzzese J. L., Evans D. B., Baker C., Chiao P. J. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9: 346–354
   PubMed Web of Science ®Google Scholar
• Fujioka S., Sclabas G. M., Schmidt C., Niu J., Frederick W. A., Dong Q. G., Abbruzzese J. L., Evans D. B., Baker C., Chiao P. J. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003; 22: 1365–1370
   PubMed Web of Science ®Google Scholar
• Wang W., Abbruzzese J. L., Evans D. B., Chiao P. J. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999; 18: 4554–4563
   PubMed Web of Science ®Google Scholar
• Chuang S. E., Yeh P. Y., Lu Y. S., Lai G. M., Liao C. M., Gao M., Cheng A. L. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002; 63: 1709–1716
   PubMed Web of Science ®Google Scholar
• Li Y., Ahmed F., Ali S., Philip P. A., Kucuk O., Sarkar F. H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005; 65: 6934–6942
   PubMed Web of Science ®Google Scholar
• Yeh P. Y., Chuang S. E., Yeh K. H., Song Y. C., Ea C. K., Cheng A. L. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol 2002; 63: 1423–1430
   PubMed Web of Science ®Google Scholar
• Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W. E., Folsch U. R., Schafer H. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002; 62: 910–916
   PubMed Web of Science ®Google Scholar
• Muerkoster S., Arlt A., Sipos B., Witt M., Grossmann M., Kloppel G., Kalthoff H., Folsch U. R., Schafer H. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 2005; 65: 1316–1324
   PubMed Web of Science ®Google Scholar
• Thiery J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002; 2: 442–454
   PubMed Web of Science ®Google Scholar
• Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L. A., Knuechel R., Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U. S. A 2001; 98: 10356–10361
   PubMed Web of Science ®Google Scholar
• Stemmer V., de C. B., Berx G., Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene 2008
   Google Scholar
• Graham T. R., Zhau H. E., Odero-Marah V. A., Osunkoya A. O., Kimbro K. S., Tighiouart M., Liu T., Simons J. W., O'Regan R. M. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68: 2479–2488
   PubMed Web of Science ®Google Scholar
• Yang M. H., Wu M. Z., Chiou S. H., Chen P. M., Chang S. Y., Liu C. J., Teng S. C., Wu K. J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10: 295–305
   PubMed Web of Science ®Google Scholar
• Spaderna S., Schmalhofer O., Wahlbuhl M., Dimmler A., Bauer K., Sultan A., Hlubek F., Jung A., Strand D., Eger A., Kirchner T., Behrens J., Brabletz T. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537–544
   PubMed Web of Science ®Google Scholar
• Yang J., Mani S. A., Donaher J. L., Ramaswamy S., Itzykson R. A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R. A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927–939
   PubMed Web of Science ®Google Scholar
• Muller T., Bain G., Wang X., Papkoff J. Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. Exp Cell Res 2002; 280: 119–133
   PubMed Web of Science ®Google Scholar
• Min C., Eddy S. F., Sherr D. H., Sonenshein G. E. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008
   Google Scholar
• Radisky D. C., Bissell M. J. NF-kappaB links oestrogen receptor signalling and EMT. Nat Cell Biol 2007; 9: 361–363
   PubMed Web of Science ®Google Scholar
• Chua H. L., Bhat-Nakshatri P., Clare S. E., Morimiya A., Badve S., Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007; 26: 711–724
   PubMed Web of Science ®Google Scholar
• Julien S., Puig I., Caretti E., Bonaventure J., Nelles L., van R. F., Dargemont C., de Herreros A. G., Bellacosa A., Larue L. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26: 7445–7456
   PubMed Web of Science ®Google Scholar
• Wang X., Belguise K., Kersual N., Kirsch K. H., Mineva N. D., Galtier F., Chalbos D., Sonenshein G. E. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007; 9: 470–478
   PubMed Web of Science ®Google Scholar
• Kong D., Wang Z., Sarkar S. H., Li Y., Banerjee S., Saliganan A., Kim H. R., Cher M. L., Sarkar F. H. PDGF-D over-expression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008; 26: 1425–1435
   PubMed Web of Science ®Google Scholar
• Chung C. H., Parker J. S., Ely K., Carter J., Yi Y., Murphy B. A., Ang K. K., El-Naggar A. K., Zanation A. M., Cmelak A. J., Levy S., Slebos R. J., Yarbrough W. G. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006; 66: 8210–8218
   PubMed Web of Science ®Google Scholar
• Zhang M., Xie X., Lee A. H., Binns C. W. Soy and isoflavone intake are associated with reduced risk of ovarian cancer in southeast China. Nutr Cancer 2004; 49: 125–130
   PubMed Web of Science ®Google Scholar
• Wu A. H., Yu M. C., Tseng C. C., Twaddle N. C., Doerge D. R. Plasma isoflavone levels versus self-reported soy isoflavone levels in Asian-American women in Los Angeles County. Carcinogenesis 2004; 25: 77–81
   PubMed Web of Science ®Google Scholar
• Hamalainen M., Nieminen R., Vuorela P., Heinonen M., Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007; 2007: 45673
   PubMed Web of Science ®Google Scholar
• Kang J. L., Lee H. W., Lee H. S., Pack I. S., Chong Y., Castranova V., Koh Y. Genistein prevents nuclear factor-kappa B activation and acute lung injury induced by lipopolysaccharide. Am J Respir Crit Care Med 2001; 164: 2206–2212
   PubMed Web of Science ®Google Scholar
• Kalhan R., Smith L. J., Nlend M. C., Nair A., Hixon J. L., Sporn P. H. A mechanism of benefit of soy genistein in asthma: inhibition of eosinophil p38-dependent leukotriene synthesis. Clin Exp Allergy 2008; 38: 103–112
   PubMed Web of Science ®Google Scholar
• Smith L. J., Holbrook J. T., Wise R., Blumenthal M., Dozor A. J., Mastronarde J., Williams L. Dietary intake of soy genistein is associated with lung function in patients with asthma. J Asthma 2004; 41: 833–843
   PubMed Web of Science ®Google Scholar
• Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P. J., Philip P. A., Abbruzzese J., Sarkar F. H. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064–9072
   PubMed Web of Science ®Google Scholar
• Li Y., Sarkar F. H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002; 8: 2369–2377
   PubMed Web of Science ®Google Scholar
• Raffoul J. J., Banerjee S., Singh-Gupta V., Knoll Z. E., Fite A., Zhang H., Abrams J., Sarkar F. H., Hillman G. G. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007; 67: 2141–2149
   PubMed Web of Science ®Google Scholar
• Takimoto C. H., Glover K., Huang X., Hayes S. A., Gallot L., Quinn M., Jovanovic B. D., Shapiro A., Hernandez L., Goetz A., Llorens V., Lieberman R., Crowell J. A., Poisson B. A., Bergan R. C. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 1213–1221
   PubMed Web of Science ®Google Scholar
• Banerjee M., Tripathi L. M., Srivastava V. M., Puri A., Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003; 25: 213–224
   PubMed Web of Science ®Google Scholar
• Rao C. V., Rivenson A., Simi B., Reddy B. S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995; 55: 259–266
   PubMed Web of Science ®Google Scholar
• Bharti A. C., Donato N., Singh S., Aggarwal B. B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053–1062
   PubMed Web of Science ®Google Scholar
• Aggarwal B. B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397–1421
   PubMed Web of Science ®Google Scholar
• Chuang S. E., Cheng A. L., Lin J. K., Kuo M. L. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 2000; 38: 991–995
   PubMed Web of Science ®Google Scholar
• Sugimoto K., Hanai H., Tozawa K., Aoshi T., Uchijima M., Nagata T., Koide Y. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002; 123: 1912–1922
   PubMed Web of Science ®Google Scholar
• Leclercq I. A., Farrell G. C., Sempoux C., dela P. A., Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004; 41: 926–934
   PubMed Web of Science ®Google Scholar
• Kim Y. S., Ahn Y., Hong M. H., Joo S. Y., Kim K. H., Sohn I. S., Park H. W., Hong Y. J., Kim J. H., Kim W., Jeong M. H., Cho J. G., Park J. C., Kang J. C. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovasc Pharmacol 2007; 50: 41–49
   PubMed Web of Science ®Google Scholar
• Reyes-Gordillo K., Segovia J., Shibayama M., Vergara P., Moreno M. G., Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta 2007; 1770: 989–996
   PubMed Web of Science ®Google Scholar
• Weisberg S. P., Leibel R., Tortoriello D. V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008; 149: 3549–3558
   PubMed Web of Science ®Google Scholar
• Duvoix A., Morceau F., Delhalle S., Schmitz M., Schnekenburger M., Galteau M. M., Dicato M., Diederich M. Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem Pharmacol 2003; 66: 1475–1483
   PubMed Web of Science ®Google Scholar
• Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F. H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006; 106: 2503–2513
   PubMed Web of Science ®Google Scholar
• Bachmeier B. E., Mohrenz I. V., Mirisola V., Schleicher E., Romeo F., Hohneke C., Jochum M., Nerlich A. G., Pfeffer U. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 2008; 29: 779–789
   PubMed Web of Science ®Google Scholar
• Lin Y. G., Kunnumakkara A. B., Nair A., Merritt W. M., Han L. Y., rmaiz-Pena G. N., Kamat A. A., Spannuth W. A., Gershenson D. M., Lutgendorf S. K., Aggarwal B. B., Sood A. K. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007; 13: 3423–3430
   PubMed Web of Science ®Google Scholar
• Aggarwal S., Takada Y., Singh S., Myers J. N., Aggarwal B. B. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004; 111: 679–692
   PubMed Web of Science ®Google Scholar
• Plummer S. M., Holloway K. A., Manson M. M., Munks R. J., Kaptein A., Farrow S., Howells L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999; 18: 6013–6020
   PubMed Web of Science ®Google Scholar
• Aggarwal B. B., Shishodia S., Takada Y., Banerjee S., Newman R. A., Bueso-Ramos C. E., Price J. E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11: 7490–7498
   PubMed Web of Science ®Google Scholar
• Sharma R. A., Euden S. A., Platton S. L., Cooke D. N., Shafayat A., Hewitt H. R., Marczylo T. H., Morgan B., Hemingway D., Plummer S. M., Pirmohamed M., Gescher A. J., Steward W. P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847–6854
   PubMed Web of Science ®Google Scholar
• Cheng A. L., Hsu C. H., Lin J. K., Hsu M. M., Ho Y. F., Shen T. S., Ko J. Y., Lin J. T., Lin B. R., Ming-Shiang W., Yu H. S., Jee S. H., Chen G. S., Chen T. M., Chen C. A., Lai M. K., Pu Y. S., Pan M. H., Wang Y. J., Tsai C. C., Hsieh C. Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895–2900
   PubMed Web of Science ®Google Scholar
• Dhillon N., Aggarwal B. B., Newman R. A., Wolff R. A., Kunnumakkara A. B., Abbruzzese J. L., Ng C. S., Badmaev V., Kurzrock R. Phase I I trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491–4499
   PubMed Web of Science ®Google Scholar
• Li L., Ahmed B., Mehta K., Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007; 6: 1276–1282
   PubMed Web of Science ®Google Scholar
• Li L., Braiteh F. S., Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 1322–1331
   PubMed Web of Science ®Google Scholar
• Nho C. W., Jeffery E. Crambene, a bioactive nitrile derived from glucosinolate hydrolysis, acts via the antioxidant response element to upregulate quinone reductase alone or synergistically with indole-3-carbinol. Toxicol Appl Pharmacol 2004; 198: 40–48
   PubMed Web of Science ®Google Scholar
• Benabadji S. H., Wen R., Zheng J. B., Dong X. C., Yuan S. G. Anticarcinogenic and antioxidant activity of diindolylmethane derivatives. Acta Pharmacol Sin 2004; 25: 666–671
   PubMed Web of Science ®Google Scholar
• Cho H. J., Seon M. R., Lee Y. M., Kim J., Kim J. K., Kim S. G., Park J. H. 3,3′-Diindolylmethane suppresses the inflammatory response to lipopolysaccharide in murine macrophages. J Nutr 2008; 138: 17–23
   PubMed Web of Science ®Google Scholar
• Kim D. J., Shin D. H., Ahn B., Kang J. S., Nam K. T., Park C. B., Kim C. K., Hong J. T., Kim Y. B., Yun Y. W., Jang D. D., Yang K. H. Chemoprevention of colon cancer by Korean food plant components. Mutat Res 2003; 523–524: 99–107
   PubMedGoogle Scholar
• Li Y., Chinni S. R., Sarkar F. H. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 2005; 10: 236–243
   Google Scholar
• Rahman K. W., Sarkar F. H. Inhibition of nuclear translocation of nuclear factor-kappaB contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 2005; 65: 364–371
   PubMed Web of Science ®Google Scholar
• Cover C. M., Hsieh S. J., Cram E. J., Hong C., Riby J. E., Bjeldanes L. F., Firestone G. L. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 1999; 59: 1244–1251
   Google Scholar
• Sarkar F. H., Li Y. Indole-3-carbinol and prostate cancer. J Nutr 2004; 134: 3493S–3498S
   Google Scholar
• Naik R., Nixon S., Lopes A., Godfrey K., Hatem M. H., Monaghan J. M. A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2006; 16: 786–790
   PubMed Web of Science ®Google Scholar
• Reed G. A., Peterson K. S., Smith H. J., Gray J. C., Sullivan D. K., Mayo M. S., Crowell J. A., Hurwitz A. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 2005; 14: 1953–1960
   PubMed Web of Science ®Google Scholar
• Mukhtar H., Ahmad N. Green tea in chemoprevention of cancer. Toxicol Sci 1999; 52: 111–117
   PubMed Web of Science ®Google Scholar
• Afaq F., Adhami V. M., Ahmad N., Mukhtar H. Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene 2003; 22: 1035–1044
   PubMed Web of Science ®Google Scholar
• Wheeler D. S., Lahni P. M., Hake P. W., Denenberg A. G., Wong H. R., Snead C., Catravas J. D., Zingarelli B. The green tea polyphenol epigallocatechin-3-gallate improves systemic hemodynamics and survival in rodent models of polymicrobial sepsis. Shock 2007; 28: 353–359
   PubMed Web of Science ®Google Scholar
• Aktas O., Prozorovski T., Smorodchenko A., Savaskan N. E., Lauster R., Kloetzel P. M., Infante-Duarte C., Brocke S., Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004; 173: 5794–5800
   PubMed Web of Science ®Google Scholar
• Abboud P. A., Hake P. W., Burroughs T. J., Odoms K., O'Connor M., Mangeshkar P., Wong H. R., Zingarelli B. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol 2008; 579: 411–417
   PubMed Web of Science ®Google Scholar
• Rizvi S. I., Zaid M. A., Anis R., Mishra N. Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes. Clin. Exp. Pharmacol. Physiol 2005; 32: 70–75
   PubMed Web of Science ®Google Scholar
• Shimada M., Mochizuki K., Sakurai N., Goda T. Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats. Biosci Biotechnol Biochem 2007; 71: 2079–2082
   PubMed Web of Science ®Google Scholar
• Song E. K., Hur H., Han M. K. Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch Pharm Res 2003; 26: 559–563
   Google Scholar
• Hastak K., Gupta S., Ahmad N., Agarwal M. K., Agarwal M. L., Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003; 22: 4851–4859
   PubMed Web of Science ®Google Scholar
• Zhang Q., Wei D., Liu J. In vivo reversal of doxorubicin resistance by (−)-epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett 2004; 208: 179–186
   PubMed Web of Science ®Google Scholar
• Shanafelt T. D., Lee Y. K., Call T. G., Nowakowski G. S., Dingli D., Zent C. S., Kay N. E. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006; 30: 707–712
   PubMed Web of Science ®Google Scholar
• Olas B., Wachowicz B., Saluk-Juszczak J., Zielinski T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res 2002; 107: 141–145
   PubMed Web of Science ®Google Scholar
• Lu C. C., Lai H. C., Hsieh S. C., Chen J. K. Resveratrol ameliorates Serratia marcescens-induced acute pneumonia in rats. J Leukoc Biol 2008; 83: 1028–1037
   PubMed Web of Science ®Google Scholar
• Yoshida Y., Shioi T., Izumi T. Resveratrol ameliorates experimental autoimmune myocarditis. Circ J 2007; 71: 397–404
   PubMed Web of Science ®Google Scholar
• Elmali N., Baysal O., Harma A., Esenkaya I., Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007; 30: 1–6
   PubMed Web of Science ®Google Scholar
• Kolgazi M., Sener G., Cetinel S., Gedik N., Alican I. Resveratrol reduces renal and lung injury caused by sepsis in rats. J Surg Res 2006; 134: 315–321
   PubMed Web of Science ®Google Scholar
• Delmas D., Jannin B., Latruffe N. Resveratrol: preventing properties against vascular alterations and ageing. Mol Nutr Food Res 2005; 49: 377–395
   PubMed Web of Science ®Google Scholar
• Rossi L., Mazzitelli S., Arciello M., Capo C. R., Rotilio G. Benefits from dietary polyphenols for brain aging and alzheimer's disease. Neurochem. Res 2008
   Google Scholar
• Scarlatti F., Sala G., Somenzi G., Signorelli P., Sacchi N., Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 2003; 17: 2339–2341
   PubMed Web of Science ®Google Scholar
• Delmas D., Rebe C., Lacour S., Filomenko R., Athias A., Gambert P., Cherkaoui-Malki M., Jannin B., Dubrez-Daloz L., Latruffe N., Solary E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 2003; 278: 41482–41490
   PubMed Web of Science ®Google Scholar
• Estrov Z., Shishodia S., Faderl S., Harris D., Van Q., Kantarjian H. M., Talpaz M., Aggarwal B. B. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003; 102: 987–995
   PubMed Web of Science ®Google Scholar
• Fulda S., Debatin K. M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337–346
   PubMed Web of Science ®Google Scholar
• Ohsugi T., Kumasaka T., Ishida A., Ishida T., Horie R., Watanabe T., Umezawa K., Yamaguchi K. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. Leuk Res 2006; 30: 90–97
   Google Scholar
• Nagai N., Izumi-Nagai K., Oike Y., Koto T., Satofuka S., Ozawa Y., Yamashiro K., Inoue M., Tsubota K., Umezawa K., Ishida S. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007; 48: 4342–4350
   PubMed Web of Science ®Google Scholar
• Kubota T., Hoshino M., Aoki K., Ohya K., Komano Y., Nanki T., Miyasaka N., Umezawa K. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res Ther 2007; 9: R97
   Web of Science ®Google Scholar
• Watanabe M., Ohsugi T., Shoda M., Ishida T., Aizawa S., Maruyama-Nagai M., Utsunomiya A., Koga S., Yamada Y., Kamihira S., Okayama A., Kikuchi H., Uozumi K., Yamaguchi K., Higashihara M., Umezawa K., Watanabe T., Horie R. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005; 106: 2462–2471
   Google Scholar
• Poma P., Notarbartolo M., Labbozzetta M., Sanguedolce R., Alaimo A., Carina V., Maurici A., Cusimano A., Cervello M., D'Alessandro N. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol 2006; 28: 923–930
   Google Scholar
• Matsumoto G., Muta M., Umezawa K., Suzuki T., Misumi K., Tsuruta K., Okamoto A., Toi M. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor. Int J Oncol 2005; 27: 1247–1255
   Google Scholar
• Cyrus T., Sung S., Zhao L., Funk C. D., Tang S., Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1282–1287
   PubMed Web of Science ®Google Scholar
• Sclabas G. M., Uwagawa T., Schmidt C., Hess K. R., Evans D. B., Abbruzzese J. L., Chiao P. J. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005; 103: 2485–2490
   PubMedGoogle Scholar
• Wong B. C., Jiang X., Fan X. M., Lin M. C., Jiang S. H., Lam S. K., Kung H. F. Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003; 22: 1189–1197
   PubMed Web of Science ®Google Scholar
• Shishodia S., Koul D., Aggarwal B. B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004; 173: 2011–2022
   PubMed Web of Science ®Google Scholar
• Ali S., El-Rayes B. F., Sarkar F. H., Philip P. A. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005; 4: 1943–1951
   PubMed Web of Science ®Google Scholar
• El-Rayes B. F., Ali S., Sarkar F. H., Philip P. A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004; 3: 1421–1426
   PubMed Web of Science ®Google Scholar
• Lev-Ari S., Zinger H., Kazanov D., Yona D., Ben-Yosef R., Starr A., Figer A., Arber N. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed. Pharmacother 2005; 59(Suppl 2)S276–S280
   Google Scholar
• Saadane A., Masters S., DiDonato J., Li J., Berger M. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol 2007; 36: 728–736
   PubMed Web of Science ®Google Scholar
• Lopez-Franco O., Hernandez-Vargas P., Ortiz-Munoz G., Sanjuan G., Suzuki Y., Ortega L., Blanco J., Egido J., Gomez-Guerrero C. Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 1864–1870
   PubMed Web of Science ®Google Scholar
• Zhang S., Lin Z. N., Yang C. F., Shi X., Ong C. N., Shen H. M. Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis 2004; 25: 2191–2199
   PubMed Web of Science ®Google Scholar
• Yip-Schneider M. T., Nakshatri H., Sweeney C. J., Marshall M. S., Wiebke E. A., Schmidt C. M. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther 2005; 4: 587–594
   PubMed Web of Science ®Google Scholar
• Lappas M., Yee K., Permezel M., Rice G. E. Sulfasalazine and BAY 11–7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 2005; 146: 1491–1497
   PubMed Web of Science ®Google Scholar
• Muerkoster S., Arlt A., Witt M., Gehrz A., Haye S., March C., Grohmann F., Wegehenkel K., Kalthoff H., Folsch U. R., Schafer H. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003; 104: 469–476
   PubMed Web of Science ®Google Scholar
• Elliott P. J., Zollner T. M., Boehncke W. H. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003; 81: 235–245
   PubMed Web of Science ®Google Scholar
• Dong Q. G., Sclabas G. M., Fujioka S., Schmidt C., Peng B., Wu T., Tsao M. S., Evans D. B., Abbruzzese J. L., McDonnell T. J., Chiao P. J. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002; 21: 6510–6519
   PubMed Web of Science ®Google Scholar
• Lu Y., Wahl L. M. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol 2005; 78: 259–265
   PubMedGoogle Scholar
• Kim K., Ryu K., Ko Y., Park C. Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 2005; 131: 59–66
   PubMed Web of Science ®Google Scholar
• Garcia M. G., Alaniz L., Lopes E. C., Blanco G., Hajos S. E., Alvarez E. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005; 29: 1425–1434
   PubMed Web of Science ®Google Scholar
• Hansson A., Marin Y. E., Suh J., Rabson A. B., Chen S., Huberman E., Chang R. L., Conney A. H., Zheng X. Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor. Int J Oncol 2005; 27: 941–948
   PubMed Web of Science ®Google Scholar